Tower Research Capital LLC TRC Increases Position in Kura Oncology, Inc. (NASDAQ:KURA)

Tower Research Capital LLC TRC boosted its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 889.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 51,852 shares of the company's stock after buying an additional 46,613 shares during the quarter. Tower Research Capital LLC TRC owned approximately 0.07% of Kura Oncology worth $452,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Marshall Wace LLP bought a new stake in shares of Kura Oncology in the 4th quarter worth approximately $8,265,000. Vanguard Group Inc. grew its stake in Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock valued at $41,973,000 after buying an additional 615,211 shares in the last quarter. Trexquant Investment LP grew its position in shares of Kura Oncology by 867.8% in the fourth quarter. Trexquant Investment LP now owns 566,945 shares of the company's stock valued at $4,938,000 after purchasing an additional 508,362 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Kura Oncology by 463.4% in the fourth quarter. Renaissance Technologies LLC now owns 597,810 shares of the company's stock valued at $5,207,000 after purchasing an additional 491,700 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Kura Oncology by 35.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company's stock worth $12,419,000 after purchasing an additional 372,196 shares in the last quarter.

Kura Oncology Price Performance

NASDAQ KURA traded up $0.15 on Monday, reaching $6.62. 149,871 shares of the company's stock traded hands, compared to its average volume of 1,155,954. The stock has a market cap of $534.91 million, a PE ratio of -2.80 and a beta of 0.50. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $23.48. The stock has a 50-day simple moving average of $6.73 and a 200 day simple moving average of $9.52. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. As a group, research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KURA has been the topic of a number of recent analyst reports. UBS Group lowered their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. StockNews.com cut shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday. Barclays dropped their price objective on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research note on Friday. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Monday, April 28th. Finally, BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $23.89.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.